about
Epidemiology of Heart Failure and Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction: Prevalence, Clinical Characteristics, and Prognostic Importance2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesEffect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failureThe neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartanSGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic reviewWhat have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelinesHow small is too small? A systematic review of center volume and outcome after cardiac transplantationRecommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of AcademicHeart failure and socioeconomic status: accumulating evidence of inequalityNeprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chancesThe diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care settingPrevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based studyA national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in ScotlandDoes aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor? Choosing between the Scylla of observational studies and the Charybdis of subgroup analysisSerum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarctionEffect of valsartan on the incidence of diabetes and cardiovascular eventsImproved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trialCardiorenal end points in a trial of aliskiren for type 2 diabetesEffect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesExpert consensus document: Echocardiography and lung ultrasonography for the assessment and management of acute heart failureThirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-AnalysisRole of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR studyThe effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trialsPlasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction StudyAldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study.Developing therapies for heart failure with preserved ejection fraction: current state and future directionsA review of quality-of-life evaluations in patients with congestive heart failure.Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.Heart failure care in low- and middle-income countries: a systematic review and meta-analysis.Clinical practice. Systolic heart failure.The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.Economics of chronic heart failure.Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct.Results of a reevaluation of cardiovascular outcomes in the RECORD trial.Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia.Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
P50
Q22252543-0DEF63F8-4AC4-45E7-8187-CF40F7E556ACQ22306358-7B713A8E-CD99-4486-887A-5C032B244E9FQ24291336-688E67EF-0593-4F29-BA98-A20E3AC7FDF5Q26747165-1A03EAB6-8355-4641-850E-37D0AC6F2DC5Q26750510-AFEC996D-3DBA-4BBB-9BAF-F54E6A3DA5FBQ26800965-2A264C88-F07C-4B40-8FE7-67419DA17AF0Q26824136-36C03934-084D-407A-9C26-E34DB44A1B7CQ26864648-576E7E35-1489-4A2D-A311-D6C587CC8D50Q27005975-798C564B-A3D0-4CB2-A236-28EEE424A3D7Q27008175-9FA8F3F5-E0D5-4095-871E-0AF4A7A6A2C9Q27012972-6D1399B7-289D-475F-BEFA-A068C8F5277EQ27027707-521F0778-D16E-44F2-A3EE-D1D2971B27D5Q28084405-B873553B-C430-40A5-8A2B-812C202B0198Q28194404-8C49C739-F4AE-47C8-846B-386B42C7684AQ28218708-C89AC461-90F2-4F33-8C68-4F884D9DB892Q28218799-B1F91567-7F5A-478E-8D70-7900940308CEQ28271905-A24293BB-99CA-4C49-9F62-FB931500C009Q28275975-BD59E30F-A7AA-4EFF-86E5-FCBDC91E692CQ28278243-2D1E909A-5EB6-4E45-AA54-98A7125E632DQ28278569-663108E4-03F3-403A-A736-00B865435DC9Q28483807-C92C11C5-8AE8-461B-A777-5E382402CB88Q29620107-855C487F-05C2-4271-ACF0-C86B3801D9FDQ29994549-93DB5B6A-465B-47E0-93F8-F5E781DE373AQ30239022-DCC697B2-4E90-406E-93F1-06234CAE10AAQ30711948-9352AB6D-AFDC-4264-B8E4-EED17DB4646FQ30914775-42618E62-693E-4079-9CEA-E2D0A8EF3E8CQ31036336-BF44E682-C2C9-419B-9F9C-A6A017F8B5A1Q33497683-0CDD9037-715D-4C97-A1C6-1F27D5B22605Q33639223-D4A4B250-83A9-4DD4-BD10-E22E115B703BQ33772175-7FE10F39-8A1A-45F8-BFA4-A176943B63D8Q33996337-D0890949-D1ED-4556-8773-7812B00A34A6Q34035760-9405D0F5-AB70-41EA-B8DB-72543F43B50BQ34093912-A24D5D8E-B163-4044-BB38-8A9308D017A0Q34209536-24AE9965-7198-4D23-A75D-0CFCDA013DF8Q34264676-B416F004-50FA-445F-AD37-3AB3390D93F8Q34360459-B482333F-B6D3-4A85-A677-A23C8A7D208CQ34360464-7429572F-DBB1-4DCD-B723-9DF0C9C2F290Q34383685-B6FE5DAF-4989-447C-B800-6B3821CB28DAQ34419217-53BCA5CC-A129-4889-8949-BDFD356406C5Q34427866-830AA130-F98E-45FC-92F5-B1217EB27A4D
P50
subject
description
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
John McMurray
@ast
John McMurray
@en
John McMurray
@es
John McMurray
@nl
type
label
John McMurray
@ast
John McMurray
@en
John McMurray
@es
John McMurray
@nl
prefLabel
John McMurray
@ast
John McMurray
@en
John McMurray
@es
John McMurray
@nl
P1006
P214
P2163
P244
P1006
P106
P1153
7202558724
P1960
n0ZdRMoAAAAJ
P2038
John_Mcmurray2
P21
P214
P2163
P244
P31
P496
0000-0002-6317-3975
P5008
P734
P735
P7859
lccn-n95800028